Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Clinical Oncology

• Publication date

  2011-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2010.32.6397PMID 21537039PMCID PMC3107744
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase 2 study of cetuximab (Erbitux) in patients with progressive or recurrent endometrial cancer

  2020cited by this paper
• A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials

  2012cited by this paper
• A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

  2010cited by this paper
• Cancer Statistics, 2010

  2010cited by this paper
• Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.

  2010cited by this paper
• A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: A trial of the Princess Margaret Hospital, The University of Chicago, and California Cancer Phase II Consortia.

  2010cited by this paper
• Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.

  2009cited by this paper
• Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.

  2008cited by this paper
• Sorafenib (SOR) in patients (pts) with advanced/recurrent uterine carcinoma (UCA) or carcinosarcoma (CS): A phase II trial of the University of Chicago, PMH, and California Phase II Consortia

  2008cited by this paper
• A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b

  2008cited by this paper
• A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

  2007cited by this paper
• Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

  2007cited by this paper
• Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.

  2007cited by this paper
• A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer

  2007cited by this paper
• Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study.

  2006cited by this paper
• Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer-NCIC IND 160.

  2006cited by this paper
• Molecular and pathologic aspects of endometrial carcinogenesis.

  2006cited by this paper
• A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study.

  2005cited by this paper
• High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma.

  2005cited by this paper
• Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study.

  2004cited by this paper
• Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study.

  2004cited by this paper
• Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group

  2004cited by this paper
• Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.

  2004cited by this paper
• Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study.

  2003cited by this paper
• A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study.

  2002cited by this paper
• Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.

  2002cited by this paper
• Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study.

  2002cited by this paper
• Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study.

  2001cited by this paper
• PTEN induces G(1) cell cycle arrest and decreases cyclin D3 levels in endometrial carcinoma cells.

  2001cited by this paper
• Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas.

  2001cited by this paper
• PTEN Induces G1 Cell Cycle Arrest and Decreases Cyclin D3 Levels in Endometrial Carcinoma Cells

  2001cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers.

  2000cited by this paper
• Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group.

  1999cited by this paper
• Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A Phase II study of the Gynecologic Oncology Group.

  1999cited by this paper
• A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study.

  1996cited by this paper
• High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.

  1996cited by this paper

• CircCLMP Suppresses Anti-Tumor Immunity by Inhibiting Activation of IRF3 and Interferon Response in Microsatellite Instability-high Endometrial Cancer

  2026cites this paper
• NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer.

  2025cites this paper
• Exploring the Role of Hypoxia and HIF-1α in the Intersection of Type 2 Diabetes Mellitus and Endometrial Cancer

  2025cites this paper
• Lenvatinib plus pembrolizumab compared to carboplatin plus paclitaxel for carboplatin and paclitaxel pretreated, recurrent, or advanced endometrial cancer

  2025cites this paper
• Genomic alterations, molecularly targeted therapy, and survival: a real-world Endometrial Cancer Molecularly Targeted Therapy Consortium cohort study.

  2025cites this paper
• Efficacy and Safety of Immune Checkpoint Inhibitors Combined with Chemotherapy or Tyrosine Kinase Inhibitors in Advanced Endometrial Cancer: A Systematic Review and Meta-Analysis

  2024cites this paper
• Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I study.

  2024cites this paper
• Lenvatinib Plus Pembrolizumab versus Doxorubicin for Advanced or Recurrent Endometrial Cancer with Short Treatment-Free Intervals Following First-Line Carboplatin Plus Paclitaxel

  2024cites this paper
• A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies

  2024influential citation
• Cost-effectiveness of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a US payer perspective.

  2024cites this paper
• The Potential Influence of Residual or Recurrent Disease on Bevacizumab Treatment Efficacy in Ovarian Cancer: Current Evidence and Future Perspectives

  2024cites this paper
• Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy (CAP 04): a single-arm phase II trial

  2024cites this paper
• Novel Molecular Targets in Endometrial Cancer: Mechanisms and Perspectives for Therapy

  2024cites this paper
• Locally advanced and metastatic endometrial cancer: Current and emerging therapies.

  2024cites this paper
• A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer.

  2024cites this paper
• A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update

  2023cites this paper
• Uterine Neoplasms, Version 1.2023

  2023cites this paper
• Molecular subtypes of endometrial cancer: Implications for adjuvant treatment strategies

  2023cites this paper
• A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer

  2023cites this paper
• Gynecologic malignancies

  2023cites this paper
• The GOG Foundation, Inc. Developmental Therapeutics Committee Phase I & Phase II Studies

  2023cites this paper
• Efficacy and safety of apatinib in patients with recurrent uterine malignancy: a prospective, single-center, single-arm, phase 2 study

  2023cites this paper
• Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study

  2023cites this paper
• Immunotherapy treatment landscape for patients with endometrial cancer: current evidence and future opportunities.

  2023cites this paper
• Current Evidence-Based Systemic Therapy for Advanced and Recurrent Endometrial Cancer.

  2023cites this paper
• Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.

  2023cites this paper
• Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8+ T cell exhaustion via TRIM14-IFN-β axis.

  2023cites this paper
• Treatment options for molecular subtypes of endometrial cancer in 2023

  2023cites this paper
• Role of HIF-1α/ERRα in Enhancing Cancer Cell Metabolism and Promoting Resistance of Endometrial Cancer Cells to Pyroptosis

  2022cites this paper
• Anlotinib in recurrent or metastatic endometrial cancer

  2022cites this paper
• PIK3R3, a regulatory subunit of PI3K, modulates ovarian cancer stem cells and ovarian cancer development and progression by integrative analysis

  2022cites this paper
• Adjuvant and first line chemotherapy use for endometrial cancer

  2022cites this paper
• Integrating Precision Medicine into the Contemporary Management of Gynecologic Cancers

  2022cites this paper
• Total pelvic exenteration for recurrent uterine malignancies – a case series

  2022cites this paper
• A phase I study of AZD2171 and Temsirolimus in patients with advanced gynecological malignancies

  2022cites this paper
• The Multi-Kinase Inhibitor Lucitanib Enhances the Antitumor Activity of Coinhibitory and Costimulatory Immune Pathway Modulators in Syngeneic Models

  2022cites this paper
• Angiogenesis: A Pivotal Therapeutic Target in the Drug Development of Gynecologic Cancers

  2022cites this paper
• Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer

  2022cites this paper
• Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.

  2022cites this paper
• Beyond mismatch repair deficiency? Pre-treatment neutrophil-to-lymphocyte ratio is associated with improved overall survival in patients with recurrent endometrial cancer treated with immunotherapy.

  2022cites this paper
• The role of CTNNB1 mutations and matrix metalloproteinases (MMPs) in anti-angiogenesis treatment of endometrial carcinoma.

  2022cites this paper
• Intercellular Communication Reveals Therapeutic Potential of Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer

  2022cites this paper
• Advanced and recurrent endometrial cancer: state of the art and future perspectives.

  2022cites this paper
• Malignant diseases of the uterus

  2022cites this paper
• A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjects

  2022cites this paper
• A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium.

  2022cites this paper
• Response rate of anticancer drugs approved by the Food and Drug Administration based on a single-arm trial

  2022cites this paper
• Immunotherapy in endometrial cancer: rationale, practice and perspectives

  2021cites this paper
• Efficacy and Safety of Bevacizumab-Combined Chemotherapy for Advanced and Recurrent Endometrial Cancer: A Systematic Review and Meta-analysis

  2021influential citation
• Tailored Therapy Based on Molecular Characteristics in Endometrial Cancer

  2021cites this paper
• Overcoming chemotherapy resistance in endometrial cancer

  2021cites this paper
• Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis.

  2021cites this paper
• Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis.

  2021cites this paper
• Pharmacological Treatment of Advanced, Persistent or Metastatic Endometrial Cancer: State of the Art and Perspectives of Clinical Research for the Special Issue “Diagnosis and Management of Endometrial Cancer”

  2021cites this paper
• Lenvatinib and pembrolizumab in the treatment of metastatic endometrial cancer: literature review and case report

  2021cites this paper
• Bevacizumab in advanced endometrial cancer.

  2021cites this paper
• Diagnostic and Therapeutic Values of Angiogenic Factors in Endometrial Cancer

  2021cites this paper
• Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy

  2021cites this paper
• Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma

  2021cites this paper
• Recurrent Endometrial Cancer: Local and Systemic Treatment Options

  2021cites this paper
• Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.

  2021cites this paper
• Molecular Aspects of Cancer Research Endometrium – The Prospect of Personalized Treatment

  2021cites this paper
• Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer.

  2021cites this paper
• Sacituzumab Govitecan, a Trop-2-Directed Antibody-Drug Conjugate, for Patients with Epithelial Cancer: Final Safety and Efficacy Results from the Phase 1/2 IMMU-132-01 Basket Trial.

  2021cites this paper
• The role of immunotherapy in the management of metastatic/recurrent female reproductive system neoplasms

  2021cites this paper
• Immunotherapy as a treatment strategy in advanced stage and recurrent endometrial cancer: review of current phase III immunotherapy clinical trials

  2021cites this paper
• Inhibition of AXL and VEGF-A Has Improved Therapeutic Efficacy in Uterine Serous Cancer

  2021cites this paper
• Obesity and altered angiogenic-related gene expression in endometrial cancer.

  2021cites this paper
• Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study

  2021cites this paper
• Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer.

  2021cites this paper
• The emerging role of molecular pathology in directing the systemic treatment of endometrial cancer

  2021cites this paper
• Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology

  2021cites this paper
• A peptide CORO1C-47aa encoded by the circular noncoding RNA circ-0000437 functions as a negative regulator in endometrium tumor angiogenesis

  2021cites this paper
• Targeting Wnt Signaling in Endometrial Cancer

  2021cites this paper
• Preclinical Efficacy and Involvement of AKT, mTOR, and ERK Kinases in the Mechanism of Sulforaphane against Endometrial Cancer

  2020cites this paper
• Genomic Determinants of De Novo Resistance to Immune Checkpoint Blockade in Mismatch Repair–Deficient Endometrial Cancer

  2020cites this paper
• FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis

  2020cites this paper
• Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer

  2020cites this paper
• The emerging role of precision medicine in the treatment of endometrial cancer

  2020cites this paper
• Molecular markers to predict prognosis and guide therapy in endometrial cancer

  2020cites this paper
• Uterine Cancer

  2020cites this paper
• Therapeutic Targets and Opportunities in Endometrial Cancer: Update on Endocrine Therapy and Nonimmunotherapy Targeted Options.

  2020cites this paper
• Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

  2020cites this paper
• Adjuvant treatment of endometrial cancer today.

  2020cites this paper
• Second-line lenvatinib in patients with recurrent endometrial cancer.

  2020cites this paper
• Molecular Targeted Therapy in Endometrial Cancer: Basis and Therapeutics

  2020cites this paper
• Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86)

  2020cites this paper
• Avanços na quimioterapia do câncer ginecológico: uma revisão

  2020cites this paper
• Angiogenesis in endometrial carcinoma: Therapies and biomarkers, current options, and future perspectives.

  2020cites this paper
• The Dawning of the Age of Personalized Medicine in Gynecologic Oncology

  2020cites this paper
• Enhancing Delivery of Small‐Molecule‐ and Cell‐Based Therapies for Ovarian Cancer Using Advanced Delivery Strategies

  2020cites this paper
• Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer

  2020cites this paper
• Recent Advances in Endometrial Cancer

  2020cites this paper
• Efficacy and Safety of Bevacizumab-Combined Chemotherapy for Advanced and Recurrent Endometrial Cancer: A Systematic Review and Meta-Analysis.

  2020cites this paper
• Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy.

  2020cites this paper
• Progress in endometrial cancer: Contributions of the former Gynecologic Oncology Group.

  2020cites this paper
• Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

  2020cites this paper
• Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence

  2020cites this paper
• Discerning Endometriosis as a Multifaceted Entity: A Comprehensive Review

  2020cites this paper
• Immunotherapy in endometrial cancer: new scenarios on the horizon

  2019influential citation